Antimicrobial stewardship program: Difference between revisions

From IDWiki
No edit summary
m (: typo)
 
(5 intermediate revisions by the same user not shown)
Line 7: Line 7:
=== Hospital Leadership Commitment ===
=== Hospital Leadership Commitment ===
* Need support from senior leadership, including chief medical officer, chief nursing officer, and director of pharmacy
* Need support from senior leadership, including chief medical officer, chief nursing officer, and director of pharmacy

* Need leaders to give time to manage the program, resource (including staffing)
* Need leaders to give time to manage the program, resource (including staffing)
* Leaders should champion the program
* Accountability and responsibilities
* Regular reporting to senior leadership
* Available expertise on infection management
* Education and practical training
* Other actions aiming at responsible antimicrobial use
* Monitoring and surveillance
* Reporting and feedback


=== Accountability ===
== Possible Interventions ==
* The leaders must be accountable for management and outcomes
* Co-leaders should have clear delineation of responsibilities and expectations


=== Pharmacy Expertise ===
* Available expertise on infection management from ID-trained pharmacists or, if none exists, general clinical pharmacists

=== Action ===
* Choose interventions that will best improve outcomes

==== Priority Interventions ====
* Prospective audit and feedback, which can be made more effective with face-to-face meetings with prescribers ("handshake stewardship")
* Preauthorization
* Preauthorization

* Prospective audit and feedback
==== Infection-Based Interventions ====
* Didactic educational activities, including lectures and pamphlets
* Facility-specific treatment guidelines, particularly for CAP, UTI, and SSTI, as well as [[sepsis]], [[Staphylococcus aureus]] infection, [[Clostridioides difficile]] infection
* Facility-specific clinical practice guidelines for common syndromes
* Review of the management of cases of [[sepsis]], [[Staphylococcus aureus]] infection, [[Clostridioides difficile]] infection
* Reducing use of antibiotics with increased risk of [[C. difficile infection]]
* Review of culture-proven invasive infections
* Prescriber-led review, including antibiotics time-outs and stop orders
* Review of planned OPAT
* Computerized clinical decision-making support at the time of prescribing

* PK monitoring and adjustment of [[aminoglycosides]] and [[vancomycin]]
==== Provider-Based Interventions ====
* Alternative dosing of β-lactams
* Antibiotic timeouts, with scheduled reassessment at 48-72 hours by the prescriber
* Interventions to increase the use of oral antibiotics for initial therapy as well as timely transition from IV to oral antibiotics
** Not a substitution for prospective audit and feedback
** May not decrease antimicrobial use, but may improve appropriateness
* Assessing penicillin allergy
** History, challenge doses, and skin testing
** May involve nurses for the assessments

==== Pharmacy-Based Interventions ====
* Documentation of indication for antibiotics can improve antibiotic use
* Automatic substitutions from IV to oral therapy
* Interventions to reduce the duration of antibiotics to shortest effective duration
* Interventions to reduce the duration of antibiotics to shortest effective duration
* Dose adjustments and optimization
* Allergy assessments and penicillin skin testing for patients with reported [[β-lactam allergy]]
** PK monitoring and adjustment of [[aminoglycosides]] and [[vancomycin]]
** Alternative dosing of β-lactams
* Duplicative therapy alerts
* Time-sensitive automatic stop orders
* Detection and prevention of [[drug-drug interactions]]
* Reducing use of antibiotics with increased risk of [[Clostridioides difficile]] infection

==== Microbiology- and Laboratory-Based Interventions ====
* Selective reporting of susceptibility testing
* Comments in microbiology reports
* Development of stratified antibiograms (e.g. by location or age)
* Development of stratified antibiograms (e.g. by location or age)
* Selective and cascade reporting of antimicrobial susceptibility
* Rapid viral testing for respiratory pathogens to reduce the use of inappropriate antibiotics
* Rapid viral testing for respiratory pathogens to reduce the use of inappropriate antibiotics
* Rapid diagnostic testing on blood specimens
* Rapid diagnostic testing on blood specimens
* Serial [[procalcitonin]] in ICU patients
* Serial procalcitonin in ICU patients

==== Nursing-Based Interventions ====
* Optimizing microbiology culture collection (see also [[Diagnostic stewardship of urine cultures]])
* IV to oral transitions
* Prompting antibiotic timeouts

=== Tracking ===

==== Antimicrobial Use ====

* Days of therapy (DOTs) or defined daily doses (DDDs)
* Standardized antimicrobial administration ratio (SAAR), which compares actual use to expected use based on a statistical model

==== Outcome Measures ====

* [[Clostridioides difficile]] infection rates
* [[Antimicrobial resistance]]
* Financial impact, though costs often stabilize after initial improvement

==== Process Measures for QI ====

* For prospective audit and feedback, tracking the types of recommendations and whether they are accepted
* For preauthorization, tracking agents that are generating requests and ensuring that preauthorization is not delaying appropriate therapy
* For facility-specific treatment guidelines, monitoring adherence
* Others can include:
** Monitoring how often antibiotic timeouts are done and if changes are made
** Evaluating medication use for select antibiotics, typically using standardized audit forms
** Monitoring conversions from IV to oral antimicrobials
** Monitoring the frequency of duplicative therapy (e.g. double anaerobic coverage)
** Assessing the appropriateness of discharge antibiotics and durations

=== Reporting ===
* Regular updates to prescribers, pharmacists, nurses, and leadership on both outcome and process measures
* Provider-specific reports with comparisons to peers can be helpful


=== Recommended Against ===
=== Education ===
* Education and practical training is helpful but not enough
* May include didactic presentations, posters, flyers, and newsletters, and mailing list emails


== Ineffective Interventions ==
* Cycling antibiotics
* Cycling antibiotics


Line 44: Line 106:
* Implementing an Antibiotic Stewardship Program: Guidelines by the IDSA and the SHEA. ''Clin Infect Dis''. 2016;62(10):e51-e77. doi: [https://doi.org/10.1093/cid/ciw118 10.1093/cid/ciw118]
* Implementing an Antibiotic Stewardship Program: Guidelines by the IDSA and the SHEA. ''Clin Infect Dis''. 2016;62(10):e51-e77. doi: [https://doi.org/10.1093/cid/ciw118 10.1093/cid/ciw118]
* IDSA and the SHEA Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. ''Clin Infect Dis''. 2007;44:159-77. doi: [https://doi.org/10.1086/510393 10.1086/510393]
* IDSA and the SHEA Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. ''Clin Infect Dis''. 2007;44:159-77. doi: [https://doi.org/10.1086/510393 10.1086/510393]
* ''The Core Elements of Hospital Antibiotic Stewardship Programs: 2019''. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.

Latest revision as of 10:51, 21 September 2022

Background

  • Program to ensure that antimicrobials are used appropriately, in order to improve patient outcomes

Core Elements

Hospital Leadership Commitment

  • Need support from senior leadership, including chief medical officer, chief nursing officer, and director of pharmacy
  • Need leaders to give time to manage the program, resource (including staffing)
  • Leaders should champion the program
  • Regular reporting to senior leadership

Accountability

  • The leaders must be accountable for management and outcomes
  • Co-leaders should have clear delineation of responsibilities and expectations

Pharmacy Expertise

  • Available expertise on infection management from ID-trained pharmacists or, if none exists, general clinical pharmacists

Action

  • Choose interventions that will best improve outcomes

Priority Interventions

  • Prospective audit and feedback, which can be made more effective with face-to-face meetings with prescribers ("handshake stewardship")
  • Preauthorization

Infection-Based Interventions

Provider-Based Interventions

  • Antibiotic timeouts, with scheduled reassessment at 48-72 hours by the prescriber
    • Not a substitution for prospective audit and feedback
    • May not decrease antimicrobial use, but may improve appropriateness
  • Assessing penicillin allergy
    • History, challenge doses, and skin testing
    • May involve nurses for the assessments

Pharmacy-Based Interventions

  • Documentation of indication for antibiotics can improve antibiotic use
  • Automatic substitutions from IV to oral therapy
  • Interventions to reduce the duration of antibiotics to shortest effective duration
  • Dose adjustments and optimization
  • Duplicative therapy alerts
  • Time-sensitive automatic stop orders
  • Detection and prevention of drug-drug interactions
  • Reducing use of antibiotics with increased risk of Clostridioides difficile infection

Microbiology- and Laboratory-Based Interventions

  • Selective reporting of susceptibility testing
  • Comments in microbiology reports
  • Development of stratified antibiograms (e.g. by location or age)
  • Rapid viral testing for respiratory pathogens to reduce the use of inappropriate antibiotics
  • Rapid diagnostic testing on blood specimens
  • Serial procalcitonin in ICU patients

Nursing-Based Interventions

Tracking

Antimicrobial Use

  • Days of therapy (DOTs) or defined daily doses (DDDs)
  • Standardized antimicrobial administration ratio (SAAR), which compares actual use to expected use based on a statistical model

Outcome Measures

Process Measures for QI

  • For prospective audit and feedback, tracking the types of recommendations and whether they are accepted
  • For preauthorization, tracking agents that are generating requests and ensuring that preauthorization is not delaying appropriate therapy
  • For facility-specific treatment guidelines, monitoring adherence
  • Others can include:
    • Monitoring how often antibiotic timeouts are done and if changes are made
    • Evaluating medication use for select antibiotics, typically using standardized audit forms
    • Monitoring conversions from IV to oral antimicrobials
    • Monitoring the frequency of duplicative therapy (e.g. double anaerobic coverage)
    • Assessing the appropriateness of discharge antibiotics and durations

Reporting

  • Regular updates to prescribers, pharmacists, nurses, and leadership on both outcome and process measures
  • Provider-specific reports with comparisons to peers can be helpful

Education

  • Education and practical training is helpful but not enough
  • May include didactic presentations, posters, flyers, and newsletters, and mailing list emails

Ineffective Interventions

  • Cycling antibiotics

Further Reading

  • How to start an antimicrobial stewardship programme in a hospital. Clin Microbiol Infect. 2019;26(4):447-453. doi: 10.1016/j.cmi.2019.08.007
  • Implementing an Antibiotic Stewardship Program: Guidelines by the IDSA and the SHEA. Clin Infect Dis. 2016;62(10):e51-e77. doi: 10.1093/cid/ciw118
  • IDSA and the SHEA Guidelines for Developing an Institutional Program to Enhance Antimicrobial Stewardship. Clin Infect Dis. 2007;44:159-77. doi: 10.1086/510393
  • The Core Elements of Hospital Antibiotic Stewardship Programs: 2019. Atlanta, GA: US Department of Health and Human Services, CDC; 2019. Available at https://www.cdc.gov/antibiotic-use/core-elements/hospital.html.